Official reprint from UpToDate®
www.uptodate.com ©2017 UpToDate, Inc. and/or its affiliates. All Rights Reserved.

Peritoneal dialysis solutions

Muhammad Alam, MD, MPH
Michelle W Krause, MD, MPH
Section Editor
Thomas A Golper, MD
Deputy Editor
Alice M Sheridan, MD


Although the ancient Egyptians were the first to describe the peritoneal cavity in approximately 3000 BC, the concept of peritoneal dialysis is relatively new. In the late 19th century, Wegner, a German investigator, was the first to use peritoneal solutions in animals; he reported that hypertonic solutions increased in volume when injected into the peritoneal cavity. Additional investigations found that hypertonic solutions increased and hypotonic solutions decreased peritoneal fluid volume [1].

Various different investigators subsequently evaluated the efficacy of treating uremia by instilling fluids into the peritoneal cavity:

Gantar instilled saline solution in the peritoneal cavity of uremic guinea pigs and subsequently treated a uremic woman with peritoneal dialysis solution containing saline.

Heusser added dextrose to the peritoneal dialysis solution to improve ultrafiltration.

In 1938, Rhoads added lactate to the peritoneal dialysis fluid to correct acidosis.

To continue reading this article, you must log in with your personal, hospital, or group practice subscription. For more information on subscription options, click below on the option that best describes you:

Subscribers log in here

Literature review current through: Nov 2017. | This topic last updated: Apr 22, 2016.
The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment. Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions. The use of this website is governed by the UpToDate Terms of Use ©2017 UpToDate, Inc.
  1. Feriani, M, La Greca, et al. CAPD Systems and Solutions. In: Textbook of Peritoneal Dialysis, Gokal, R, Nolph, KD (Eds), Kluwer Academic Publishers, Netherlands 1994.
  2. Raja RM, Kramer MS, Manchanda R, et al. Peritoneal dialysis with fructose dialysate. Prevention of hyperglycemia and hyperosmolality. Ann Intern Med 1973; 79:511.
  3. Bischel MD, Barbour BH. Peritoneal dialysis with sorbitol versus dextrose dialysate. Clinical findings and alterations of blood and cerebrospinal fluid. Nephron 1974; 12:449.
  4. Matthys E, Dolkart R, Lameire N. Extended use of glycerol containing dialysate in diabetic CAPD patients. Perit Dial Bull 1987; 7:10.
  5. McIntyre CW. Update on peritoneal dialysis solutions. Kidney Int 2007; 71:486.
  6. Vanholder RC, Lameire NH. Osmotic agents in peritoneal dialysis. Kidney Int Suppl 1996; 56:S86.
  7. Teitelbaum I, Burkart J. Peritoneal dialysis. Am J Kidney Dis 2003; 42:1082.
  8. Gokal R. Peritoneal dialysis solutions: nutritional aspects. Perit Dial Int 1997; 17 Suppl 3:S69.
  9. Stein A, Peers E, Hattersley J, et al. Clinical experience with icodextrin in CAPD patients. Perit Dial Int 1994; 14 Suppl:51.
  10. Lee JH, Reddy DK, Saran R, et al. Advanced glycosylation end-products in diabetic rats on peritoneal dialysis using various solutions. Perit Dial Int 2000; 20:643.
  11. Plum J, Gentile S, Verger C, et al. Efficacy and safety of a 7.5% icodextrin peritoneal dialysis solution in patients treated with automated peritoneal dialysis. Am J Kidney Dis 2002; 39:862.
  12. Finkelstein F, Healy H, Abu-Alfa A, et al. Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol 2005; 16:546.
  13. Li PK, Culleton BF, Ariza A, et al. Randomized, controlled trial of glucose-sparing peritoneal dialysis in diabetic patients. J Am Soc Nephrol 2013; 24:1889.
  14. Diaz-Buxo JA, Passlick-Deetjen J, Gotloib L. Potential hazards of polyglucose. ASAIO J 2001; 47:602.
  15. Seow YY, Iles-Smith H, Hirst H, Gokal R. Icodextrin-associated peritonitis among CAPD patients. Nephrol Dial Transplant 2003; 18:1951.
  16. Cho Y, Johnson DW, Badve S, et al. Impact of icodextrin on clinical outcomes in peritoneal dialysis: a systematic review of randomized controlled trials. Nephrol Dial Transplant 2013; 28:1899.
  17. Baxter Extraneal hypoglycemia testing program is condition of FDA approval. "The Pink Sheet" 2003; 65:6.
  18. Riley SG, Chess J, Donovan KL, Williams JD. Spurious hyperglycaemia and icodextrin in peritoneal dialysis fluid. BMJ 2003; 327:608.
  19. Floré KM, Delanghe JR. Analytical interferences in point-of-care testing glucometers by icodextrin and its metabolites: an overview. Perit Dial Int 2009; 29:377.
  20. Han SH, Ahn SV, Yun JY, et al. Effects of icodextrin on patient survival and technique success in patients undergoing peritoneal dialysis. Nephrol Dial Transplant 2012; 27:2044.
  21. Klein E, Ward RA, Williams TE, Feldhoff PW. Peptides as substitute osmotic agents for glucose in peritoneal dialysate. ASAIO Trans 1986; 32:550.
  22. Imholz AL, Lameire N, Faict D, et al. Evaluation of short-chain polypeptides as an osmotic agent in continuous ambulatory peritoneal dialysis patients. Perit Dial Int 1994; 14:215.
  23. Hain H, Schütte W, Pustelnik A, et al. Ultrafiltration and absorption characteristics of hydroxyethylstarch and dextran during long dwell peritoneal dialysis exchanges in rats. Adv Perit Dial 1989; 5:28.
  24. Grodstein GP, Blumenkrantz MJ, Kopple JD, et al. Glucose absorption during continuous ambulatory peritoneal dialysis. Kidney Int 1981; 19:564.
  25. Sitter T, Sauter M. Impact of glucose in peritoneal dialysis: saint or sinner? Perit Dial Int 2005; 25:415.
  26. Williams JD, Topley N, Craig KJ, et al. The Euro-Balance Trial: the effect of a new biocompatible peritoneal dialysis fluid (balance) on the peritoneal membrane. Kidney Int 2004; 66:408.
  27. Lee HY, Park HC, Seo BJ, et al. Superior patient survival for continuous ambulatory peritoneal dialysis patients treated with a peritoneal dialysis fluid with neutral pH and low glucose degradation product concentration (Balance). Perit Dial Int 2005; 25:248.
  28. Johnson DW, Brown FG, Clarke M, et al. Effects of biocompatible versus standard fluid on peritoneal dialysis outcomes. J Am Soc Nephrol 2012; 23:1097.
  29. Lui SL, Yung S, Yim A, et al. A combination of biocompatible peritoneal dialysis solutions and residual renal function, peritoneal transport, and inflammation markers: a randomized clinical trial. Am J Kidney Dis 2012; 60:966.
  30. Woodrow G. Can biocompatible dialysis fluids improve outcomes in peritoneal dialysis patients? Perit Dial Int 2005; 25:230.
  31. Diaz-Buxo JA, Gotloib L. Agents that modulate peritoneal membrane structure and function. Perit Dial Int 2007; 27:16.
  32. Ikizler TA, Hakim RM. Nutrition in end-stage renal disease. Kidney Int 1996; 50:343.
  33. Young GA, Kopple JD, Lindholm B, et al. Nutritional assessment of continuous ambulatory peritoneal dialysis patients: an international study. Am J Kidney Dis 1991; 17:462.
  34. Blumenkrantz MJ, Gahl GM, Kopple JD, et al. Protein losses during peritoneal dialysis. Kidney Int 1981; 19:593.
  35. Young GA, Brownjohn AM, Parsons FM. Protein losses in patients receiving continuous ambulatory peritoneal dialysis. Nephron 1987; 45:196.
  36. Bergström J, Fürst P, Alvestrand A, Lindholm B. Protein and energy intake, nitrogen balance and nitrogen losses in patients treated with continuous ambulatory peritoneal dialysis. Kidney Int 1993; 44:1048.
  37. Jones MR, Gehr TW, Burkart JM, et al. Replacement of amino acid and protein losses with 1.1% amino acid peritoneal dialysis solution. Perit Dial Int 1998; 18:210.
  38. Shockley TR, Martis L, Tranaeus AP. New solutions for peritoneal dialysis in adult and pediatric patients. Perit Dial Int 1999; 19 Suppl 2:S429.
  39. Garosi G, Gaggiotti E, Monaci G, et al. Biocompatibility of a peritoneal dialysis solution with amino acids: histological evaluation in the rabbit. Perit Dial Int 1998; 18:610.
  40. Kopple JD, Bernard D, Messana J, et al. Treatment of malnourished CAPD patients with an amino acid based dialysate. Kidney Int 1995; 47:1148.
  41. Faller B. Amino acid-based peritoneal dialysis solutions. Kidney Int Suppl 1996; 56:S81.
  42. Bazzato G, Coli U, Landini S, et al. Xylitol as osmotic agent in CAPD: an alternative to glucose for uremic diabetic patients? Trans Am Soc Artif Intern Organs 1982; 28:280.
  43. Heaton A, Ward MK, Johnston DG, et al. Evaluation of glycerol as an osmotic agent for continuous ambulatory peritoneal dialysis in end-stage renal failure. Clin Sci (Lond) 1986; 70:23.
  44. Feriani M. Buffers: bicarbonate, lactate and pyruvate. Kidney Int Suppl 1996; 56:S75.
  45. Mactier RA, Sprosen TS, Gokal R, et al. Bicarbonate and bicarbonate/lactate peritoneal dialysis solutions for the treatment of infusion pain. Kidney Int 1998; 53:1061.
  46. Feriani M, Kirchgessner J, La Greca G, Passlick-Deetjen J. Randomized long-term evaluation of bicarbonate-buffered CAPD solution. Kidney Int 1998; 54:1731.
  47. Feriani M, Dissegna D, La Greca G, Passlick-Deetjen J. Short-term clinical study with bicarbonate-containing peritoneal dialysis solution. Perit Dial Int 1993; 13:296.
  48. Cancarini GC, Faict D, De Vos C, et al. Clinical evaluation of a peritoneal dialysis solution with 33 mmol/L bicarbonate. Perit Dial Int 1998; 18:576.
  49. Feriani M, Passlick-Deetjen J, Jaeckle-Meyer I, et al. Individualized bicarbonate concentrations in the peritoneal dialysis fluid to optimize acid-base status in CAPD patients. Nephrol Dial Transplant 2004; 19:195.
  50. Montenegro J, Saracho RM, Martínez IM, et al. Long-term clinical experience with pure bicarbonate peritoneal dialysis solutions. Perit Dial Int 2006; 26:89.
  51. Montenegro J, Saracho R, Gallardo I, et al. Use of pure bicarbonate-buffered peritoneal dialysis fluid reduces the incidence of CAPD peritonitis. Nephrol Dial Transplant 2007; 22:1703.
  52. Ahmad S, Sehmi JS, Ahmad-Zakhi KH, et al. Impact of new dialysis solutions on peritonitis rates. Kidney Int Suppl 2006; :S63.
  53. Gupta A, Amin NB, Besarab A, et al. Dialysate iron therapy: infusion of soluble ferric pyrophosphate via the dialysate during hemodialysis. Kidney Int 1999; 55:1891.
  54. Bastani B, Galley S. Intraperitoneal iron-dextran as a potential route of iron therapy in CAPD patients. Perit Dial Int 1996; 16:646.
  55. Sánchez C, López-Barea F, Sánchez-Cabezudo J, et al. Low vs standard calcium dialysate in peritoneal dialysis: differences in treatment, biochemistry and bone histomorphometry. A randomized multicentre study. Nephrol Dial Transplant 2004; 19:1587.
  56. Bro S, Brandi L, Daugaard H, Olgaard K. Calcium concentration in the CAPD dialysate: what is optimal and is there a need to individualize? Perit Dial Int 1997; 17:554.
  57. Weinreich T. Low or high calcium dialysate solutions in peritoneal dialysis? Kidney Int Suppl 1996; 56:S92.